ENERGY Study
Contact
Description
The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.
You may be able to join the study if you are:
- 18 years of age or older
- Diagnosed with wAIHA for at least 3 months
- Currently receiving treatment or have previously received treatment for wAIHA
- Have platelet counts of more than 30,000/ L and Hemoglobin less than 10 g/dL
Other study requirements will apply.
Eligibility and criteria
IRB Number:
19-016799
Eligible age range:
Clinical trial phase:
Phase II
Phase III
Official title:
What to expect
Related specialties

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.